Home > > > > > Report Detail

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Understanding and Treatment Algorithm

The market report provides the overview of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Report Insights

- Patient Population in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

- Therapeutic Approaches in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

- Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Analysis

- Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size and Trends

- Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Opportunities

- Impact of upcoming Therapies in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Report Assessment

- Current Treatment Practices in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

- Unmet Needs in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market

- Organize sales and marketing efforts by identifying the best opportunities for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market

- To understand the future market competition in the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Overview at a Glance
2.1. Market Share Distribution of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 2016
2.2. Market Share Distribution of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 2028
3. Disease Background and Overview: Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM
4.3. Total Prevalent Patient Population of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM - By Countries
5. Epidemiology of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.1.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.1.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.1.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.1.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.4.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.4.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.4.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.4.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.5.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.5.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.5.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.5.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.6.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.6.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.6.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.6.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.7.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.7.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.7.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.7.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.8.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.8.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.8.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.8.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.9.3. Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.9.4. Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) *
5.9.5. Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
5.9.6. Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) : 7MM Market Analysis
12.1. 7MM Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
12.2. 7MM Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
12.3. 7MM Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products
13. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States
13.1.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States
13.1.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany
13.2.1.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany
13.2.1.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France
13.2.2.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France
13.2.2.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy
13.2.3.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy
13.2.3.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain
13.2.4.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain
13.2.4.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United Kingdom
13.2.5.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan
13.3.2. Percentage Share of drugs marketed for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan
13.3.3. Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Table 6: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Table 7: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Table 12: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Table 15: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Table 16: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Table 17: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Table 22: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Table 27: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Table 31: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Table 32: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Table 37: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 42:7MM- Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 45: United States-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 48: Germany-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 51: France-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 54: Italy-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 57: Spain-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 60:UK-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Table 63: Japan-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Figure 7: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Figure 12: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Figure 16: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Figure 17: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Figure 22: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Figure 27: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Figure 32: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Figure 37: Treatable Cases of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 42:7MM- Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 45: United States-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 48: Germany-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 51: France-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 54: Italy-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 57: Spain-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 60:UK-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) in USD MM (2016-2028)
Figure 63: Japan-Market Share Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) by Therapies in USD MM (2016-2028)

  • Global Thoracic Surgery Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Thoracic Surgery market: According to our latest research, the global Thoracic Surgery market looks promising in the next 5 years. As of 2022, the global Thoracic Surgery market was estimated at USD 3777.06 million, and it's anticipated to reach USD 4689.46 million in 2028, with a CAGR of 3.67% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Thoracic Su......
  • Global Angina Pectoris Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 125
    Report Overview: The Global Angina Pectoris Treatment Market Size was estimated at USD 8809.40 million in 2022 and is projected to reach USD 9981.15 million by 2029, exhibiting a CAGR of 1.80% during the forecast period. This report provides a deep insight into the global Angina Pectoris Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche marke......
  • Global Dilated Cardiomyopathy Therapeutics Market Status and Outlook 2023-2028
    Published: 22-Nov-2023        Price: US 3160 Onwards        Pages: 100
     Dilated cardiomyopathy is currently defined by the presence of left ventricular (LV) or biventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for ea......
  • Global Transcatheter Mitral Valve Replacement Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Transcatheter Mitral Valve Replacement market: According to our latest research, the global Transcatheter Mitral Valve Replacement market looks promising in the next 5 years. As of 2022, the global Transcatheter Mitral Valve Replacement market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a dee......
  • Global Thoracic Surgery Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 92
    Thoracic surgery is a procedure to treat medical conditions involving heart and lungs. It includes therapies such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. Market Analysis and Insights: Global Thoracic Surgery Market The global Thoracic Surgery market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth......
  • Global Angina Pectoris Treatment Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 29-Jun-2023        Price: US 3260 Onwards        Pages: 120
    The Angina Pectoris Treatment market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Angina Pectoris Treatment industry, and breaks down according to the type, application, and consumption area of Angina Pectoris Treatment. The report also introduces players in the industry from the perspective of the industry chain and marketing ......
  • Global Transcatheter Mitral Valve Replacement Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 15-Jun-2023        Price: US 3260 Onwards        Pages: 109
    The Transcatheter Mitral Valve Replacement market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Transcatheter Mitral Valve Replacement industry, and breaks down according to the type, application, and consumption area of Transcatheter Mitral Valve Replacement. The report also introduces players in the industry from the perspecti......
  • Global Angina Pectoris Treatment Market Size, Share and Industry Analysis by Regions, Countries, Types, and Applications, Forecast to 2028
    Published: 19-May-2023        Price: US 3480 Onwards        Pages: 105
    The global Angina Pectoris Treatment market size was valued at USD XX Million in 2022 and will reach USD XX Million in 2028, with a CAGR of XX% during 2022-2028. The Angina Pectoris Treatment market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types......
  • Global Thoracic Surgery Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 16-May-2023        Price: US 3260 Onwards        Pages: 100
    The Thoracic Surgery market revenue was 3777.06 Million USD in 2022, and will reach 4689.46 Million USD in 2028, with a CAGR of 3.67% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Thoracic Surgery industry, and breaks down according to the type, application, and consumption area of Thoracic Surgery. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and descr......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs